Featured

Status

Health Topics

Any Category
Diseases
Clear Filters

Search Clinical Trials

213 Results
Recruiting
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
A healthy donor has given blood to make LMP/BARF1/EBNA-1 MABEL CTLs in the lab. We made the cells by first growing a special type of cells called activated T cells …
Baylor Role: Lead Sponsor
Active, Not Recruiting
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Blood will be collected from the patient to make LMP/BARF1/EBNA1 (NPC)-specific T cells. To grow NPC-specific T cells we have to use special cells called antigen-presenting cells, which train the …
Baylor Role: Lead Sponsor
Completed
The Feasibility of Self or Partner-assisted Digital Anal Exam Screening
There is no standard screening protocol for anal cancer even as disease incidence and mortality increases; however, a digital anorectal exam (also called a digital rectal exam) will play a …
Baylor Role: Collaborator
Completed
CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients
The profound symptom burden associated with advanced lung cancer (LC) makes caregiving a complex and burdensome task. Despite the input of outpatient palliative care services, LC families are often unprepared …
Baylor Role: Lead Sponsor
Completed
Improving Self-Management in Head and Neck Cancer
Patients treated with radiation (XRT) for head and neck cancers (HNCs) experience significant side effects such as abnormally reduced salivation, difficulty swallowing, and taste changes even after they have been …
Baylor Role: Lead Sponsor
Completed
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in tuberous sclerosis complex 1 (TSC1) or tuberous sclerosis complex 2 (TSC2) tumor suppressor genes. TSC is characterized …
Terminated
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy until disease progression or …
Baylor Role: Collaborator
Active, Not Recruiting
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
The subject or his/her donor will give blood to make CD19/CD28 chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the T cells, the …
Baylor Role: Lead Sponsor
Withdrawn
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
The main study part has 3 phases. The first phase is called the baseline phase and consists of 1-2 study site visit(s). During this phase, the investigators will gather information …
Baylor Role: Lead Sponsor
Active, Not Recruiting
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Patients give blood to make GD2-T cells that are grown and frozen. To get the GD2-CAR to attach to the surface of the T-cell, a gene is inserted into the …
Baylor Role: Lead Sponsor